Trinity Biotech (TRIB) Liabilities and Shareholders Equity (2009 - 2025)

Trinity Biotech has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $105.2 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 1.82% year-over-year to $105.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $405.5 million (up 5.22% YoY) and the FY2025 annual result came in at $105.2 million, up 1.82% from the prior year.
• Liabilities and Shareholders Equity grew to $105.2 million in Q4 2025 per TRIB's latest filing, from $99.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $136.0 million in Q1 2021 and troughed at $59.4 million in Q4 2023.
• A 5-year average of $99.0 million and a median of $98.8 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 35.47% in 2023, then surged 73.79% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $118.9 million in 2021, then decreased by 22.53% to $92.1 million in 2022, then tumbled by 35.47% to $59.4 million in 2023, then soared by 73.79% to $103.3 million in 2024, then increased by 1.82% to $105.2 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $105.2 million, $99.6 million, and $103.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.